It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Stimulator of interferon genes (STING) contributes to immune responses against tumors and may control viral infection including SARS-CoV-2 infection. However, activation of the STING pathway by airway silica or smoke exposure leads to cell death, self-dsDNA release, and STING/type I IFN dependent acute lung inflammation/ARDS. The inflammatory response induced by a synthetic non-nucleotide-based diABZI STING agonist, in comparison to the natural cyclic dinucleotide cGAMP, is unknown. A low dose of diABZI (1 µg by endotracheal route for 3 consecutive days) triggered an acute neutrophilic inflammation, disruption of the respiratory barrier, DNA release with NET formation, PANoptosis cell death, and inflammatory cytokines with type I IFN dependent acute lung inflammation. Downstream upregulation of DNA sensors including cGAS, DDX41, IFI204, as well as NLRP3 and AIM2 inflammasomes, suggested a secondary inflammatory response to dsDNA as a danger signal. DNase I treatment, inhibition of NET formation together with an investigation in gene-deficient mice highlighted extracellular DNA and TLR9, but not cGAS, as central to diABZI-induced neutrophilic response. Therefore, activation of acute cell death with DNA release may lead to ARDS which may be modeled by diABZI. These results show that airway targeting by STING activator as a therapeutic strategy for infection may enhance lung inflammation with severe ARDS.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 CNRS -UMR7355, Orleans Cedex 2, France; University of Orleans, Rue de la Ferollerie, Experimental and Molecular Immunology and Neurogenetics, Orleans, France (GRID:grid.112485.b) (ISNI:0000 0001 0217 6921)
2 CNRS -UMR7355, Orleans Cedex 2, France (GRID:grid.112485.b); University of Orleans, Rue de la Ferollerie, Experimental and Molecular Immunology and Neurogenetics, Orleans, France (GRID:grid.112485.b) (ISNI:0000 0001 0217 6921)
3 Artimmune SAS, Orleans, France (GRID:grid.112485.b)
4 University of Orleans, Rue de la Ferollerie, Experimental and Molecular Immunology and Neurogenetics, Orleans, France (GRID:grid.112485.b) (ISNI:0000 0001 0217 6921); Genetics department, Regional Hospital Orleans (CHRO), Orleans, France (GRID:grid.413932.e) (ISNI:0000 0004 1792 201X)
5 CNRS -UMR7355, Orleans Cedex 2, France (GRID:grid.413932.e); University of Orleans, Rue de la Ferollerie, Experimental and Molecular Immunology and Neurogenetics, Orleans, France (GRID:grid.112485.b) (ISNI:0000 0001 0217 6921); Artimmune SAS, Orleans, France (GRID:grid.112485.b)




